Literature DB >> 29529256

Clinical and echocardiographic factors associated with mitral plasticity in patients with chronic inferior myocardial infarction.

Nydia Ávila-Vanzzini1, Hector I Michelena2, Juan Francisco Fritche Salazar1, Héctor Herrera-Bello3, Silvia Siu Moguel4, Rubén Rafael Rodríguez Ocampo5, Diego Javier Oregel Camacho5, Nilda Espínola Zavaleta1.   

Abstract

Aims: Ischaemic mitral regurgitation (IMR) is consequence of left ventricular (LV) remodelling after myocardial infarction. In some cases, the mitral valve enlarges to compensate for LV remodelling and tenting, improving its coaptation; a process termed 'plasticity'. We sought to identify clinical and echocardiographic factors associated with plasticity in patients with chronic inferior myocardial infarction (CII). Methods and results: This study included 91 revascularized CII patients and 46 controls. Plasticity and IMR severity were evaluated by 2D transthoracic echocardiography. Compared with controls, CII patients were older (59 vs. 25 years) and mostly men (80% vs. 46%), both P < 0.001. Chronic inferior myocardial infarction patients also had significant LV remodelling: larger LV volumes, larger mitral tenting areas, larger coaptation depths, longer mitral leaflets and chords, and worse mitral regurgitation (all P ≤ 0.03). Of 91 CII patients, 60 had mitral plasticity (longer anterior and posterior leaflets and longer posterior chords, all P < 0.001), despite not exhibiting significantly larger LV volumes, tenting area or coaptation depth, when compared with patients with no plasticity. Contralateral (anterior) papillary muscle-to-annulus length tended to be increased in CII plasticity patients (P = 0.05). Also they had less moderate and severe IMR (both P < 0.04) compared with non-plasticity CII patients. Multivariate analysis demonstrated independent associations between plasticity and smoking [odds ratio (OR) 0.03, 0.002-0.57; P = 0.019], duration of type-2 diabetes (OR 1.19, 1.007-1.42; P = 0.04) and haemoglobin (OR 2.17, 1.25-3.76; P = 0.005).
Conclusion: Mitral plasticity results in less moderate and severe IMR. Longer time-duration of diabetes mellitus and higher haemoglobin level are independently associated with mitral plasticity, while smoking independently associates with no plasticity. Increased anterior papillary muscle-to-annulus length in CII patients with plasticity suggests complex LV remodelling mechanisms are involved in plasticity.

Entities:  

Mesh:

Year:  2018        PMID: 29529256     DOI: 10.1093/ehjci/jey021

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  5 in total

1.  Simulation of Mitral Valve Plasticity in Response to Myocardial Infarction.

Authors:  Bruno V Rego; Amir H Khalighi; Joseph H Gorman; Robert C Gorman; Michael S Sacks
Journal:  Ann Biomed Eng       Date:  2022-08-27       Impact factor: 4.219

Review 2.  Ischemic Mitral Regurgitation: A Multifaceted Syndrome with Evolving Therapies.

Authors:  Mattia Vinciguerra; Francesco Grigioni; Silvia Romiti; Giovanni Benfari; David Rose; Cristiano Spadaccio; Sara Cimino; Antonio De Bellis; Ernesto Greco
Journal:  Biomedicines       Date:  2021-04-21

3.  Pre-surgical Prediction of Ischemic Mitral Regurgitation Recurrence Using In Vivo Mitral Valve Leaflet Strains.

Authors:  Harshita Narang; Bruno V Rego; Amir H Khalighi; Ahmed Aly; Alison M Pouch; Robert C Gorman; Joseph H Gorman Iii; Michael S Sacks
Journal:  Ann Biomed Eng       Date:  2021-04-09       Impact factor: 4.219

4.  Commentary: Surgical mitral plasticity: Another brick in the wall?

Authors:  Antonio M Calafiore; Theodoros Kofidis; Mario Gaudino
Journal:  JTCVS Open       Date:  2020-04-03

5.  Mitral valve leaflet response to ischaemic mitral regurgitation: from gene expression to tissue remodelling.

Authors:  Daniel P Howsmon; Bruno V Rego; Estibaliz Castillero; Salma Ayoub; Amir H Khalighi; Robert C Gorman; Joseph H Gorman; Giovanni Ferrari; Michael S Sacks
Journal:  J R Soc Interface       Date:  2020-05-06       Impact factor: 4.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.